Literature DB >> 9106042

High-performance liquid chromatographic assay for cefepime in serum.

H Elkhaïli1, L Linger, H Monteil, F Jehl.   

Abstract

A simple, rapid, specific and sensitive high-performance liquid chromatographic method was developed for the determination of cefepime 1-[[(6R, 7R)-7-[2-(2-amino-4-thiazolyl) glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo- [4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium hydroxide, inner salt, 7(2)-(Z)-(O-methyloxime) in human serum. Separation was achieved on a reversed-phase Ultrasphere XL-ODS column (75 x 4.6 mm I.D.). The mobile phase was 7% acetonitrile in 20 mM ammonium acetate (pH 4). Cefepime eluted in the range of 1.8-2.2 min. Detection was by UV absorbance at 254 nm. The lower limit of quantitation of cefepime in plasma was 0.5 microgram/ml. The average absolute recovery was 106.2 +/- 2.1%. The linear range was from 0.1 to 50 micrograms/ml, with a correlation coefficient greater than 0.999. The within-day C.V.s for human samples were 4.9 and 2.3% for 1 and 50 micrograms/ml, respectively. The between-day C.V.s for human serum samples were 14.5, 7.4 and 6.7 for 1, 25 and 50 micrograms/ml, respectively. Cefepime was found to be unstable in serum at room temperature. For delayed assay, samples must be stored at -80 degrees C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106042     DOI: 10.1016/s0378-4347(96)00406-9

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  7 in total

1.  Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro.

Authors:  Denis Bugnon; Eric Giannoni; Paul Majcherczyk; Michel P Glauser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.

Authors:  J Lipman; S C Wallis; C Rickard
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 3.  Review on Characterization, Properties, and Analytical Methods of Cefepime.

Authors:  Omkulthom Al Kamaly
Journal:  Int J Anal Chem       Date:  2022-06-29       Impact factor: 1.698

4.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

5.  Stability and antibacterial activity of cefepime during continuous infusion.

Authors:  Pål F Sprauten; Paul M Beringer; Stan G Louie; Timothy W Synold; Mark A Gill
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates.

Authors:  James M Kidd; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

7.  Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

Authors:  O Robineau; E Talagrand-Reboulh; B Brunschweiler; F Jehl; E Beltrand; F Rousseau; N Blondiaux; A Grillon; C Joseph; P Lambotte; P Boyer; Eric Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-20       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.